The EU Ozempic probe is expanding. What you should know – GLOBAL

July 11, 2023

The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk’s NOVOb.CO diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class.

The agency began its review on July 3 after Iceland’s health regulator flagged the reports of patients thinking about suicide and one case of thoughts of self harm after use of Novo’s drugs.

There have been issues of suicidal thoughts linked to another class of weight-loss drugs, which have hobbled previous attempts by the drug industry to develop lucrative weight-loss drugs.

Sanofi’s weight-loss drug Acomplia, which never won U.S. approval, was withdrawn in Europe in 2008 after being linked to suicidal thoughts.

Read more:

NationTalk Partners & Sponsors Learn More